Coronary heart disease and dynamics of intracardiac haemodynamics after hospitalisation for COVID-19: Results of a 12-month follow-up study

  • Received 10.08.2024

  • Revised 28.10.2024

  • Accepted 26.11.2024



  • 1,189 Views

  • Retrieved from Vol. 6, No. 4, 2024

  • Pages 23-33

The study aimed to evaluate the dynamics of intracardiac haemodynamics in patients with coronary heart disease (CHD) after COVID-19 over 12 months. To achieve this goal, patients with COVID-19 and diagnosed with CHD were monitored at the clinical sites of the Bogomolets National Medical University and the cardiology department of the Road Clinical Hospital No. 2, Kyiv Clinical Hospital No. 18, and the Medbud Medical Centre. The main parameters studied were left ventricular ejection fraction (LVEF), end-diastolic volume (EDV), cardiac output, troponins I and T, natriuretic peptide, and C-reactive protein levels. The study determined that LVEF decreased to 47% in the 3rd month after COVID-19 and partially recovered to 52% in 12 months, but did not reach the control values. The EDV increased to 160 ml at month 3 and then decreased to 147 ml at month 12, indicating a volume overload of the left ventricle. Cardiac output at the beginning of the study was 3.8 l/min, and at the end – 4.3 l/min, which indicated positive dynamics, but incomplete recovery. The levels of troponins and natriuretic peptide were initially elevated, but gradually decreased to normal levels, indicating the recovery of cardiac function. The elevated level of C-reactive protein recorded at the beginning of the study indicated the presence of an active inflammatory process, which gradually decreased to normal values over 12 months. This is a substantial indicator of inflammation reduction and improvement of the general condition of patients after COVID-19. The results of the study indicated a partial recovery of heart function in patients but also demonstrated that the recovery process is long and does not always result in a complete return to normal cardiac function

heart failure; inflammatory process; myocardial recovery; functional heart disorders; cardiac markers

https://doi.org/10.63341/bmbr/4.2024.23

[1] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. DOI: 10.1016/S1473-3099(20)30120-1

[2] He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020;92(7):719–25. DOI: 10.12/jmv.25766

[3] Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect Dis Poverty. 2020;9:29. DOI: 10.1186/s40249-020-00646-x

[4] Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7):1470–7. DOI: 10.3201/eid2607.200282

[5] Lakhani HV, Pillai SS, Zehra M, Sharma I, Sodhi K. Systematic review of clinical insights into novel coronavirus (CoVID-19) pandemic: Persisting challenges in U.S. rural population. Int J Environ Res Public Health. 2020;17(12):4279. DOI: 10.3390/ijerph17124279

[6] Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SK, Al Katheeri R, et al. Global epidemiology of ischemic heart disease: Results from the global burden of disease study. Cureus. 2020;12(7):e9349. DOI: 10.7759/cureus.9349

[7] Szarpak L, Mierzejewska M, Jurek J, Kochanowska A, Gasecka A, Truszewski Z, et al. Effect of coronary artery disease on COVID-19 – prognosis and risk assessment: A systematic review and meta-analysis. Biology (Basel). 2022;11(2):221. DOI: 10.3390/biology11020221

[8] Ganatra S, Dani SS, Shah S, Asnani A, Neilan TG, Lenihan D, et al. Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic. Trends Cardiovasc Med. 2020;30(6):315–25. DOI: 10.1016/j.tcm.2020.05.004

[9] Wang S, Zhu R, Zhang C, Guo Y, Lv M, Zhang C, et al. Effects of the pre-existing coronary heart disease on the prognosis of COVID-19 patients: A systematic review and meta-analysis. PloS One. 2023;18(10):e0292021. DOI: 10.1371/journal.pone.0292021

[10] Kaddoura R, Salam AM. Thrombosis management and challenges in COVID-19 patients presenting with acute coronary syndromes. Heart Views. 2020;21(3):195–208. DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_143_20

[11] Basu-Ray I, Almaddah NK, Vaqar S, Soos MP. Cardiac manifestations of coronavirus (COVID-19) [Internet]. Treasure Island: StatPearls Publishing; 2024 [cited 2024 Sep 29]. Available from: https://pubmed.ncbi.nlm.nih.gov/32310612/

[12] Pannucci P, Jefferson SR, Hampshire J, Cooper SL, Hill SJ, Woolard J. COVID-19-induced myocarditis: Pathophysiological roles of ACE2 and toll-like receptors. Int J Mol Sci. 2023;24(6):5374. DOI: 10.3390/ijms24065374

[13] Kounis NG, Gogos C, de Gregorio C, Hung MY, Kounis SN, Tsounis EP, et al. “When,” “where,” and “how” of SARS-CoV-2 infection affects the human cardiovascular system: A narrative review. Balkan Med J. 2024;41(1):7–22. DOI: 10.4274/balkanmedj.galenos.2023.2023-10-25

[14] Taylor RS, Dalal HM, McDonagh ST. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol. 2022;19(3):180–94. DOI: 10.1038/s41569-021-00611-7

[15] Dalal HM, Taylor RS, Wingham J, Greaves CJ, Jolly K, Lang CC, et al. A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: A research programme including the REACH-HF RCT. Programme Grants Appl Res. 2021;9(1). DOI: 10.3310/pgfar09010

[16] Cao J, Dong R, Zhang K, Zhang H. Effects of myocardial viability and left ventricular remodeling on survival of patients with heart failure and reduced ejection fraction after coronary artery bypass grafting. Cardiovasc Diagn Ther. 2020;10(2):183–92. DOI: 10.21037/cdt.2020.01.11

[17] Weinmann K, Werner J, Koenig W, Rottbauer W, Walcher D, Keßler M. Use of cardiac biomarkers for monitoring improvement of left ventricular function by immunoadsorption treatment in dilated cardiomyopathy. Biomolecules. 2019;9(11):654. DOI: 10.3390/biom9110654

[18] Topf A, Mirna M, Bacher N, Paar V, Motloch LJ, Ohnewein B, et al. Analysis of selected cardiovascular biomarkers in Takotsubo cardiomyopathy and the most frequent cardiomyopathies. Front Cardiovasc Med. 2021;8:700169. DOI: 10.3389/fcvm.2021.700169

[19] Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: Basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518–36. DOI: 10.1016/j.jacbts.2020.04.002

[20] Karagodin I, Singulane CC, Descamps T, Woodward GM, Xie M, Tucay ES, et al. Ventricular changes in patients with acute COVID–19 infection: Follow-up of the World Alliance Societies of Echocardiography (WASE-COVID) study. J Am Soc Echocardiogr. 2022;35(3):295–304. DOI: 10.1016/j.echo.2021.10.015

[21] Castillo EC, Vázquez-Garza E, Yee-Trejo D, García-Rivas G, Torre-Amione G. What is the role of the inflammation in the pathogenesis of heart failure? Curr Cardiol Rep. 2020;22(11):139. DOI: 10.1007/s11886-020-01382-2

[22] Mesquita T, Lin YN, Ibrahim A. Chronic low-grade inflammation in heart failure with preserved ejection fraction. Aging Cell. 2021;20(9):e13453. DOI: 10.1111/acel.13453

[23] Sharma D, Rohila A, Deora S, Garg MK, Misra S. Cardiac assessment of patients during post COVID-19 recovery phase: A prospective observational study. Glob Cardiol Sci Pract. 2022;2022(3):18. DOI: 10.21542/gcsp.2022.18

[24] Alqahtani MS, Abbas M, Alsabaani A, Alqarni A, Almohiy HM, Alsawqaee E, et al. The potential impact of COVID-19 virus on the heart and the circulatory system. Infect Drug Resist. 2022;2022(15):1175–89. DOI: 10.2147/IDR.S351318

[25] Ntchana A, Shrestha S, Pippin M. Cardiovascular complications of COVID-19: A scoping review of evidence. Cureus. 2023;15(11):e48275. DOI: 10.7759/cureus.48275

[26] Polito MV, Silverio A, Bellino M, Iuliano G, Di Maio M, Alfano C, et al. Cardiovascular involvement in COVID-19: What sequelae should we expect? Cardiol Ther. 2021;10(2):377–96. DOI: 10.1007/s40119-021-00232-8

[27] Vazirani R, Feltes G, Hoyo RS, Viana-Llamas MC, Raposeiras-Roubín S, Romero R, et al. Elevated troponins after COVID-19 hospitalization and long-term COVID-19 symptoms: Incidence, prognosis, and clinical outcomes – results from a multi-center international prospective registry (HOPE-2). J Clin Med. 2024;13(9):2596. DOI: 10.3390/jcm13092596

[28] Lionte C, Sorodoc V, Haliga RE, Bologa C, Ceasovschih A, Petris OR, et al. Inflammatory and cardiac biomarkers in relation with post-acute COVID-19 and mortality: What we know after successive pandemic waves. Diagnostics (Basel). 2022;12(6):1373. DOI: 10.3390/diagnostics12061373

[29] Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of cardiac natriuretic peptides in heart structure and function. Int J Mol Sci. 2022;23(22):14415. DOI: 10.3390/ijms232214415

[30] Tobler DL, Pruzansky AJ, Naderi S, Ambrosy AP, Slade JJ. Long-term cardiovascular effects of COVID-19: Emerging data relevant to the cardiovascular clinician. Curr Atheroscler Rep. 2022;24(7):563–70. DOI: 10.1007/s11883-022-01032-8

[31] Arévalos V, Ortega-Paz L, Rodríguez-Arias JJ, Calvo López M, Castrillo-Golvano L, Salazar-Rodríguez A, et al. Acute and chronic effects of COVID-19 on the cardiovascular system. J Cardiovasc Dev Dis. 2021;8(10):128. DOI: 10.3390/jcdd8100128

[32] The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. [cited 2024 Jul 18]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki/

[33] Rahman A, Ruge M, Hlepas A, Nair G, Gomez J, du Fay de Lavallaz J, et al. Hyperdynamic left ventricular ejection fraction is associated with higher mortality in COVID-19 patients. Am Heart J Plus. 2022;14:100134. DOI: 10.1016/j.ahjo.2022.100134

[34] Narovlyanskaya O, Winokur EJ. Viral myocarditis. Dimens Crit Care Nurs. 2020;39(2):75–80. DOI: 10.1097/DCC.0000000000000402

[35] Ghantous E, Topilsky Y. Recovery of cardiac function following COVID-19. Eur J Heart Fail. 2021;23(11):1913–5. DOI: 10.1002/ejhf.2364

[36] Ferdinandy P, Andreadou I, Baxter GF, Botker HE, Davidson SM, Dobrev D, et al. Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning. Pharmacol Rev. 2023;75(1):159–216. DOI: 10.1124/pharmrev.121.000348

[37] Kapoor PM, Bhardwaj V, Sharma A, Kiran U. Global end-diastolic volume an emerging preload marker vis-a-vis other markers – have we reached our goal? Ann Card Anaesth. 2016;19(4):699–704. DOI: 10.4103/0971-9784.191554

[38] Badrinath A, Bhatta S, Kloc A. Persistent viral infections and their role in heart disease. Front Microbiol. 2022;13:1030440. DOI: 10.3389/fmicb.2022.1030440

[39] Olszanecka A, Wojciechowska W, Bednarek A, Kusak P, Wizner B, Terlecki M, et al. Serial echocardiographic evaluation of COVID-19 patients without prior history of structural heart disease: A 1-year follow-up CRACoV-HHS study. Front Cardiovasc Med. 2023;10:1230669. DOI: 10.3389/fcvm.2023.1230669

[40] Nunez-Gil IJ, Feltes G, Viana-Llamas MC, Raposeiras-Roubin S, Romero R, Alfonso-Rodríguez E, et al. Post-COVID-19 symptoms and heart disease: Incidence, prognostic factors, outcomes and vaccination: Results from a multi-center international prospective registry (HOPE 2). J Clin Med. 2023;12(2):706. DOI: 10.3390/jcm12020706

[41] Szekely Y, Lichter Y, Sadon S, Lupu L, Taieb P, Banai A, et al. Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. J Am Soc Echocardiogr. 2021;34(12):1273–84. DOI: 10.1016/j.echo.2021.08.022

[42] Zhao D, He Y, Dian Y, Meng Y, Zeng F, Deng G. Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients. J Infect. 2023;87(2):148–50. DOI: 10.1016/j.jinf.2023.03.026

[43] Brunner-La Rocca HP, Sanders-van Wijk S. Natriuretic peptides in chronic heart failure. Card Fail Rev. 2019;5(1):44–9. DOI: 10.15420/cfr.2018.26.1

[44] Benhuri B, Aikawa T, Takagi H, Benhuri D, Kuno T. Elevated natriuretic peptides in patients with severe or critical COVID-19: A meta-analysis. Tex Heart Inst J. 2022;49(5):e207404. DOI: 10.14503/THIJ-20-7404

[45] Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. DOI: 10.3389/fimmu.2018.00754

[46] Cui Z, Merritt Z, Assa A, Mustehsan H, Chung E, Liu S, et al. Early and significant reduction in C-reactive protein levels after corticosteroid therapy is associated with reduced mortality in patients with COVID-19. J Hosp Med. 2021;16(3):142–8. DOI: 10.12788/jhm.3560

[47] Parhizgar P, Yazdankhah N, Rzepka AM, Chung KY, Ali I, Lai Fat Fur R, et al. Beyond acute COVID-19: A review of long-term cardiovascular outcomes. Can J Cardiol. 2023;39(6):726–40. DOI: 10.1016/j.cjca.2023.01.031

[48] Yajima T. Viral myocarditis: Potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol. 2011;6(5):551–66. DOI: 10.2217/fmb.11.40

[49] Kanuri SH, Sirrkay PJ, Ulucay AS. COVID-19 heart unveiling as atrial fibrillation: Pathophysiology, management and future directions for research. Egypt Heart J. 2023;75(1):36. DOI: 10.1186/s43044-023-00359-0